Last reviewed · How we verify

Risedronate — Competitive Intelligence Brief

Risedronate (Risedronate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Bone.

marketed Butyrophilin subfamily 3 member A1, Farnesyl pyrophosphate synthase, Farnesyl diphosphate synthase Bone Small molecule Live · refreshed every 30 min

Target snapshot

Risedronate (Risedronate) — Toronto Rehabilitation Institute.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Risedronate TARGET Risedronate Toronto Rehabilitation Institute marketed Butyrophilin subfamily 3 member A1, Farnesyl pyrophosphate synthase, Farnesyl diphosphate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Risedronate — Competitive Intelligence Brief. https://druglandscape.com/ci/risedronate. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: